Johnny Hu

As a principal at Menlo Ventures, Johnny invests in biotech and life science companies with a focus on novel therapeutics and new technologies for improving medical outcomes. He has firsthand experience working at the bench on engineering new tools for the clinic. While completing his Ph.D., Johnny helped develop gene editing technologies that were licensed by companies such as Editas Medicine (NASDAQ: EDIT) and Beam Therapeutics (NASDAQ: BEAM). He is excited about partnering with founders at the beginning of the company journey to translate groundbreaking science into new medicines. Prior to Menlo, Johnny was a vice president at Longitude Capital, where he made several investments in early-stage biotech companies. He was a board observer at Lexeo Therapeutics, Endeavor Biomedicines, and Opna IO, and was on the investment team for Amunix Pharmaceuticals. Before Longitude, he was an associate at Omega Funds, where he worked on the firm’s investment in Nuvation Bio (NYSE: NUVB).